All Bristol-Myers Squibb articles – Page 2
-
Business
BMS sues executive for joining rival company
Bristol-Myers Squibb’s lawsuit against its former immuno-oncology chief who left to work for AstraZeneca has implications for biopharma industry
-
Business
BMS invests in gene therapy
Bristol-Myers Squibb makes $100 million deal with biotech uniQure
-
Business
BMS bolsters immuno-oncology with pair of deals
Firm will acquire Flexus Biosciences and collaborate with Rigel
-
Business
Clinical collaborations drive cancer immunotherapy
Companies race to pair up chemotherapy drugs with immune system-boosting antibodies to greatest effect in trials
-
Business
First of a new breed of anticancer antibodies approved in Japan
Ono claims Opdivo is the first anti-PD1 treatment in the world
-
Business
EMA wrangles restrain trial data progress
Attempts to balance industry and research interests on transparency draw suggestions of improper collusion
-
Business
Pharma vies to unleash immune system power on cancer
Immuno-oncological drugs look set to earn billions and significantly lengthen patients’ lives
-
Business
Bristol-Myers Squibb to close Irish plant
130 jobs to go at manufacturing site in Cruiserath
-
Business
AstraZeneca shells out $4.1bn for diabetes business
Bristol-Myers Squibb exits the diabetes field with plans to become a specialised biopharmaceutical company
-
Business
New wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
-
News
Chemist sentenced to life
Tianle Li, who poisoned her husband with thallium, has been sentenced to life imprisonment
-
News
Chemist found guilty of murder
Tianle Li poisoned her husband with thallium obtained from the lab where she worked
-
Feature
From molecules to medicines
Turning an active drug molecule into a finished product requires as much chemistry as developing the drug in the first place, as Phillip Broadwith discovers
-
Business
Amylin headquarters to close with further job losses
Bristol-Myers Squibb plans to shutter the San Diego, US, site following last year’s merger
-
Business
BMS sells OTC drugs for $482m
Bristol-Myers Squibb will offload rights to a range of over-the-counter products to Reckitt Benckiser
-
Business
India pushes for emergency drug licences
Government looks set to force licensing of three patented cancer drugs
-
Business
Patent woes lead to sharp sales losses
Bristol-Myers Squibb, AstraZeneca and Eli Lilly have all suffered loss of exclusivity for key drugs
-
Business
BMS and AstraZeneca buy Amylin for $7bn
Two pharma giants have teamed up to buy US biotech Amylin, responsible for the Byetta and Bydureon anti-diabetes brands
- Previous Page
- Page1
- Page2
- Next Page